View Future GrowthHeidelberg Pharma 과거 순이익 실적과거 기준 점검 0/6Heidelberg Pharma 의 수입은 연평균 -6.5%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 9.3%의 비율로 감소해 왔습니다.핵심 정보-6.52%순이익 성장률4.72%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-9.30%자기자본이익률n/a순이익률-1,261.93%다음 순이익 업데이트15 Jul 2026최근 과거 실적 업데이트공시 • Mar 12+ 1 more updateHeidelberg Pharma AG to Report Fiscal Year 2025 Results on Mar 26, 2026Heidelberg Pharma AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Mar 26, 2026공시 • Jan 24+ 1 more updateHeidelberg Pharma AG to Report Q2, 2025 Results on Jul 10, 2025Heidelberg Pharma AG announced that they will report Q2, 2025 results on Jul 10, 2025Reported Earnings • Oct 11Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023)Third quarter 2024 results: €0.13 loss per share (down from €0.002 profit in 3Q 2023). Revenue: €3.56m (up 59% from 3Q 2023). Net loss: €5.59m (down €5.71m from profit in 3Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 12Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)Second quarter 2024 results: €0.086 loss per share (improved from €0.20 loss in 2Q 2023). Revenue: €5.02m (up 117% from 2Q 2023). Net loss: €4.17m (loss narrowed 56% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 26First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)First quarter 2024 results: €0.10 loss per share (improved from €0.14 loss in 1Q 2023). Revenue: €1.86m (down 10% from 1Q 2023). Net loss: €4.49m (loss narrowed 32% from 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.44 loss per share. Revenue: €16.8m (down 9.9% from FY 2022). Net loss: €20.3m (loss widened 3.3% from FY 2022). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is expected to decline by 6.3% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Germany are expected to grow by 17%.모든 업데이트 보기Recent updates공시 • Jun 25Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory BoardHeidelberg Pharma AG at its ordinary annual general meeting held on June 23, 2026, approved the Election of Mr. Jack Yefei Ling as new member of the Supervisory Board.Price Target Changed • May 20Price target decreased by 12% to €5.50Down from €6.25, the current price target is provided by 1 analyst. New target price is 105% above last closing price of €2.68. Stock is down 18% over the past year. The company is forecast to post a net loss per share of €0.52 next year compared to a net loss per share of €0.91 last year.공시 • May 19Heidelberg Pharma AG, Annual General Meeting, Jun 23, 2026Heidelberg Pharma AG, Annual General Meeting, Jun 23, 2026, at 09:00 W. Europe Standard Time.공시 • Apr 07Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual MeetingHeidelberg Pharma AG will present promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration-resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA, from 17 to 22 April. Details of the conference and poster presentation are as follow: Poster: HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression. Poster number: 5639. Session: Antibody-Drug Conjugates and Linker Engineering 4. Presentation time: 21 April, 2:00 pm – 5:00 pm PDT. HDP-103 demonstrates target specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models representative of mCRPC, including tumors with heterogeneous PSMA expression and those harboring a del(17p). In these models, Amanitin-based HDP-103 was superior to an anti-PSMA Exatecan ADC. Adverse events with HDP-103 in non-human primates were restricted to known off-target effects of Amanitin-based ADCs, primarily in the liver and kidney. These effects can be readily monitored and are transient. HDP-103 serum levels demonstrate stability of the ADC in circulation, no evidence of drug accumulation, no differences between sexes, and dose-linearity. The potent anti-tumor efficacy of HDP-103 combined with a favorable half-life and a manageable safety profile, leads to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC. HDP-103´s unique mode of action gives it advantages over other treatment modalities in use or development for mCRPC including in patients with del(17p) who have a high unmet medical need.공시 • Mar 12+ 1 more updateHeidelberg Pharma AG to Report Fiscal Year 2025 Results on Mar 26, 2026Heidelberg Pharma AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Mar 26, 2026공시 • Nov 25+ 1 more updateHeidelberg Pharma AG Announces Board Changes, Effective 24 November 2025Heidelberg Pharma AG announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board, with immediate effect. Dr Liu has stepped down from his position as a member of the Supervisory Board of Heidelberg Pharma, with effect as of 23 December 2025. His permanent appointment as Chairman of the Executive Management Board will become effective as of 24 December 2025. For the transition period from 24 November 2025 until 23 December 2025 he will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz). Dr Liu is Chief Scientific Officer (CSO) and President of Huadong Global Development at Huadong Medicine in Hangzhou, China. Prior to that he held various leading positions in the pharma industry in the US, including GlaxoSmithKline, Wyeth (now Pfizer) and Forest Labs (now Abbvie). His more than 25 years of industry experience include clinical and preclinical research & development of medicinal products, including ADC products.공시 • Sep 26+ 1 more updateHeidelberg Pharma AG Plans Significant Reduction in the Workforce by Approx. 75% by Mid-2026Heidelberg Pharma AG announced that Executive Management Board plans to reduce the workforce companywide by approximately 75% by mid-2026.Breakeven Date Change • Aug 18No longer forecast to breakevenThe 2 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €94.9m in 2027. New consensus forecast suggests the company will make a loss of €33.6m in 2027.공시 • Jul 11Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2025Heidelberg Pharma AG provided earnings guidance for the fiscal year 2025. For the period, the company expected sales revenue and other income to be in the range of EUR 9 million to EUR 11 million and operating loss to be in the range of EUR 30 million to EUR 35 million.공시 • Apr 07Heidelberg Pharma AG, Annual General Meeting, May 15, 2025Heidelberg Pharma AG, Annual General Meeting, May 15, 2025, at 09:00 W. Europe Standard Time.공시 • Mar 22Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2025Heidelberg Pharma AG provided earnings guidance for the fiscal year 2025. The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 9.0 million and EUR 11.0 million in sales revenue and other income (2024: EUR 12.0 million) in the 2025 fiscal year. Operating loss expected to be EUR 30.0 million to EUR 35.0 million.공시 • Jan 24+ 1 more updateHeidelberg Pharma AG to Report Q2, 2025 Results on Jul 10, 2025Heidelberg Pharma AG announced that they will report Q2, 2025 results on Jul 10, 2025공시 • Jan 13Heidelberg Pharma AG Progresses into Cohort 7 in A Phase I/IIa Study with Bcma Atac Candidate HDP-101 Targeting Multiple MyelomaHeidelberg Pharma AG announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose optimization regimens were introduced with three different settings. HDP-101 was well tolerated in Cohort 6, and the company are looking forward to publishing first efficacy and additional safety data of this patient group at forthcoming scientific conferences in 2025. Heidelberg Pharma's Phase I/IIa clinical study is an ongoing, non-randomised, open label study that is actively enrolling patients with relapsed or refractory Multiple myeloma or other plasma cell disorders expressing BCMA (B-cell maturation antigen). The study is currently assessing the safety, tolerability, pharmacokinetics, and efficacy of HDP-101 in patients with multiple myeloma. Clinical data from Cohort 5 demonstrated complete remission in one patient who had been heavily pre-treated across nine prior lines of therapy, including another BCMA-targeting agent. This patient showed an objective improvement (" partial response") in the 2nd cycle of treatment, with complete remission observed after the 11th cycle and continues sustaining response for more than a year.Breakeven Date Change • Dec 30No longer forecast to breakevenThe 2 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €22.4m in 2026. New consensus forecast suggests the company will make a loss of €39.0m in 2026.Reported Earnings • Oct 11Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023)Third quarter 2024 results: €0.13 loss per share (down from €0.002 profit in 3Q 2023). Revenue: €3.56m (up 59% from 3Q 2023). Net loss: €5.59m (down €5.71m from profit in 3Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 12Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)Second quarter 2024 results: €0.086 loss per share (improved from €0.20 loss in 2Q 2023). Revenue: €5.02m (up 117% from 2Q 2023). Net loss: €4.17m (loss narrowed 56% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.New Risk • May 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€34m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€34m free cash flow). Earnings have declined by 13% per year over the past 5 years.Reported Earnings • Apr 26First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)First quarter 2024 results: €0.10 loss per share (improved from €0.14 loss in 1Q 2023). Revenue: €1.86m (down 10% from 1Q 2023). Net loss: €4.49m (loss narrowed 32% from 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.44 loss per share. Revenue: €16.8m (down 9.9% from FY 2022). Net loss: €20.3m (loss widened 3.3% from FY 2022). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is expected to decline by 6.3% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Germany are expected to grow by 17%.Price Target Changed • Mar 08Price target increased by 14% to €8.85Up from €7.75, the current price target is provided by 1 analyst. New target price is 177% above last closing price of €3.19. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.53 last year.공시 • Dec 12+ 2 more updatesHeidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024Heidelberg Pharma AG announced that they will report first half, 2024 results on Jul 11, 2024New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).Price Target Changed • Oct 25Price target decreased by 13% to €7.75Down from €8.87, the current price target is provided by 1 analyst. New target price is 176% above last closing price of €2.81. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.53 last year.Reported Earnings • Oct 13Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)Third quarter 2023 results: EPS: €0.002 (up from €0.14 loss in 3Q 2022). Revenue: €9.50m (up 170% from 3Q 2022). Net income: €113.1k (up €4.73m from 3Q 2022). Profit margin: 1.2% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Germany are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.New Risk • Oct 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.2% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (€32m net loss next year).공시 • Sep 19Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101Heidelberg Pharma AG announced that the clinical Phase I/IIa study with the lead development candidate HDP-101 has already started to recruit patients for the fifth patient cohort with a dosing of 100 µg/kg. The Safety Review Committee's (SRC) evaluation of patient data concluded that no dose-limiting toxicities have occurred to date. The first four dose levels have shown to be safe and well tolerated. So far 12 patients have been treated in the trial. With the expansion of study sites this summer, patient enrollment has significantly accelerated. One patient from the third cohort has now been on HDP-101 monotherapy for over nine months and has been treated with eleven doses. The BCMA antibody Amanitin conjugate HDP-101 is being tested in an open-label, multicenter study for the treatment of relapsed or refractory multiple myeloma, a cancer of the bone marrow. The first part of the study is a Phase I dose escalation study to determine the maximum tolerated dose of HDP-101. These findings will be used to determine the dose for the Phase IIa part, the primary objective of which is to initially evaluate the anti-tumor activity of HDP-101. The open-label, multicenter Phase I/IIa trial is expected to enroll up to 36 patients in the first part and up to 30 patients in the second part. Patients in Phase IIa will be stratified based on 17p deletion status. Preclinical data show that Amanitin has the potential to work particularly well on those tumors that have been genetically altered by a so-called 17p deletion to bypass a particular protective mechanism of cells. Patients with such a deletion generally respond less well to standard therapies and have a significantly poorer prognosis. Phase IIa will not only validate the efficacy of HDP-101 in patients with multiple myeloma, but also the clinical relevance of the 17p deletion.Reported Earnings • Jul 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €2.50m (down 78% from 2Q 2022). Net loss: €9.39m (loss widened €8.03m from 2Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany.공시 • May 09Heidelberg Pharma Ag Announces Executive ChangesHeidelberg Pharma AG announced that Walter Miller has been appointed Chief Financial Officer effective May 1, 2023. dr Jan Schmidt-Brand, who has held a dual role since 2014, will remain Spokesman of the Management Board/CEO and will hand over his responsibilities as CFO to Walter Miller. Walter Miller was most recently CFO of Optimapharm Group, a Clinical Research Organization (CRO) headquartered in Zagreb, Croatia, where he was responsible for finance, MA and administration. He has many years of experience in corporate finance, MA, strategic controlling, accounting and corporate development, both in biotech companies and at CROs. Before Optimapharm, Mr. Miller was CFO at Mologen AG, Berlin, and CFO at the Nuvisan Group, headquartered in Neu-Ulm, as well as more than ten years in senior finance positions at Santhera Pharmaceuticals, Pratteln, Switzerland. He holds a degree in business administration from Aachen University.Price Target Changed • Apr 27Price target decreased by 19% to €8.87Down from €10.97, the current price target is an average from 3 analysts. New target price is 118% above last closing price of €4.06. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.70 next year compared to a net loss per share of €0.53 last year.Price Target Changed • Apr 12Price target decreased by 19% to €8.87Down from €10.97, the current price target is an average from 3 analysts. New target price is 108% above last closing price of €4.27. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.70 next year compared to a net loss per share of €0.53 last year.Breakeven Date Change • Mar 28No longer forecast to breakevenThe 3 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €24.0m in 2025. New consensus forecast suggests the company will make a loss of €27.0m in 2025.Reported Earnings • Mar 27Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: €0.53 loss per share (improved from €0.80 loss in FY 2021). Revenue: €19.9m (up €17.8m from FY 2021). Net loss: €19.7m (loss narrowed 25% from FY 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Price Target Changed • Feb 07Price target decreased by 8.0% to €10.30Down from €11.20, the current price target is an average from 3 analysts. New target price is 106% above last closing price of €5.00. Stock is up 19% over the past year. The company is forecast to post a net loss per share of €0.64 next year compared to a net loss per share of €0.80 last year.Reported Earnings • Oct 14Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)Third quarter 2022 results: €0.14 loss per share (improved from €0.17 loss in 3Q 2021). Revenue: €4.67m (up €4.11m from 3Q 2021). Net loss: €4.62m (loss narrowed 20% from 3Q 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Reported Earnings • Jul 13Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)Second quarter 2022 results: €0.04 loss per share (up from €0.22 loss in 2Q 2021). Revenue: €11.3m (up €10.7m from 2Q 2021). Net loss: €1.36m (loss narrowed 80% from 2Q 2021). Over the next year, revenue is forecast to grow 6.3%, compared to a 30% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Reported Earnings • May 01First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: €0.21 loss per share (down from €0.20 loss in 1Q 2021). Revenue: €829.0k (up 124% from 1Q 2021). Net loss: €7.25m (loss widened 15% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 295%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Price Target Changed • Mar 03Price target increased to €10.78Up from €9.95, the current price target is an average from 2 analysts. New target price is 101% above last closing price of €5.35. Stock is down 29% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.61 last year.Reported Earnings • Oct 08Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: €633.8k (down 86% from 3Q 2020). Net loss: €5.76m (loss widened 89% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.Executive Departure • Sep 03CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the companyDuring their tenure, earnings grew by 23% annually compared to the industry average of 20%. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Breakeven Date Change • Jul 12Forecast to breakeven in 2023The 4 analysts covering Heidelberg Pharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 12% per year to 2022. The company is expected to make a profit of €4.00m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Reported Earnings • Jul 09Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: €712.1k (down 56% from 2Q 2020). Net loss: €6.77m (loss widened 40% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.Reported Earnings • May 01First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €461.5k (down 69% from 1Q 2020). Net loss: €6.32m (loss widened 38% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.Reported Earnings • Mar 27Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €9.58m (up 28% from FY 2019). Net loss: €18.4m (loss widened 81% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 17New 90-day high: €8.28The company is up 77% from its price of €4.69 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Price Target Changed • Feb 08Price target raised to €6.52Up from €5.62, the current price target is an average from 3 analysts. The new target price is 5.6% below the current share price of €6.90. As of last close, the stock is up 164% over the past year.Is New 90 Day High Low • Dec 04New 90-day high: €5.32The company is up 30% from its price of €4.10 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.40 per share.Is New 90 Day High Low • Nov 16New 90-day high: €4.88The company is up 9.0% from its price of €4.47 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.19 per share.Is New 90 Day High Low • Oct 21New 90-day low: €3.55The company is down 22% from its price of €4.53 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €18.94 per share.Reported Earnings • Oct 09Third quarter earnings releasedOver the last 12 months the company has reported total losses of €17.0m, with losses widening by 71% from the prior year. Total revenue was €8.80m over the last 12 months, up 27% from the prior year.Is New 90 Day High Low • Sep 29New 90-day low: €3.83The company is down 19% from its price of €4.70 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.87 per share.매출 및 비용 세부 내역Heidelberg Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:HPHA 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비28 Feb 263-4183830 Nov 251-4283931 Aug 253-2672731 May 254-2372528 Feb 257-2172330 Nov 247-1972231 Aug 248-1972231 May 2410-1372429 Feb 249-1862730 Nov 2310-2062831 Aug 239-2253131 May 2311-2752928 Feb 2320-1962630 Nov 2219-2062631 Aug 2217-2162231 May 2213-2262028 Feb 222-2752030 Nov 212-2641931 Aug 212-2541931 May 217-2242028 Feb 217-2041930 Nov 209-1841831 Aug 2010-1741731 May 207-1541529 Feb 208-1241230 Nov 197-1031131 Aug 197-1031131 May 196-1131128 Feb 194-1231230 Nov 184-1231131 Aug 184-1131031 May 183-1131028 Feb 182-1131030 Nov 172-113931 Aug 172-103831 May 172-82728 Feb 172-72630 Nov 162-62631 Aug 162-74631 May 162-74529 Feb 162-75530 Nov 153-75431 Aug 153-535양질의 수익: HPHA 은(는) 현재 수익성이 없습니다.이익 마진 증가: HPHA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HPHA은 수익성이 없으며 지난 5년 동안 손실이 연평균 6.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HPHA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HPHA은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HPHA의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/12 11:13종가2026/07/10 00:00수익2026/02/28연간 수익2025/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Heidelberg Pharma AG는 9명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bruno BulicBaader Helvea Equity ResearchChristian WeizBaader Helvea Equity ResearchRobin DavisonEdison Investment Research6명의 분석가 더 보기
공시 • Mar 12+ 1 more updateHeidelberg Pharma AG to Report Fiscal Year 2025 Results on Mar 26, 2026Heidelberg Pharma AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Mar 26, 2026
공시 • Jan 24+ 1 more updateHeidelberg Pharma AG to Report Q2, 2025 Results on Jul 10, 2025Heidelberg Pharma AG announced that they will report Q2, 2025 results on Jul 10, 2025
Reported Earnings • Oct 11Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023)Third quarter 2024 results: €0.13 loss per share (down from €0.002 profit in 3Q 2023). Revenue: €3.56m (up 59% from 3Q 2023). Net loss: €5.59m (down €5.71m from profit in 3Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 12Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)Second quarter 2024 results: €0.086 loss per share (improved from €0.20 loss in 2Q 2023). Revenue: €5.02m (up 117% from 2Q 2023). Net loss: €4.17m (loss narrowed 56% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 26First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)First quarter 2024 results: €0.10 loss per share (improved from €0.14 loss in 1Q 2023). Revenue: €1.86m (down 10% from 1Q 2023). Net loss: €4.49m (loss narrowed 32% from 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.44 loss per share. Revenue: €16.8m (down 9.9% from FY 2022). Net loss: €20.3m (loss widened 3.3% from FY 2022). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is expected to decline by 6.3% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Germany are expected to grow by 17%.
공시 • Jun 25Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory BoardHeidelberg Pharma AG at its ordinary annual general meeting held on June 23, 2026, approved the Election of Mr. Jack Yefei Ling as new member of the Supervisory Board.
Price Target Changed • May 20Price target decreased by 12% to €5.50Down from €6.25, the current price target is provided by 1 analyst. New target price is 105% above last closing price of €2.68. Stock is down 18% over the past year. The company is forecast to post a net loss per share of €0.52 next year compared to a net loss per share of €0.91 last year.
공시 • May 19Heidelberg Pharma AG, Annual General Meeting, Jun 23, 2026Heidelberg Pharma AG, Annual General Meeting, Jun 23, 2026, at 09:00 W. Europe Standard Time.
공시 • Apr 07Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual MeetingHeidelberg Pharma AG will present promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration-resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA, from 17 to 22 April. Details of the conference and poster presentation are as follow: Poster: HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression. Poster number: 5639. Session: Antibody-Drug Conjugates and Linker Engineering 4. Presentation time: 21 April, 2:00 pm – 5:00 pm PDT. HDP-103 demonstrates target specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models representative of mCRPC, including tumors with heterogeneous PSMA expression and those harboring a del(17p). In these models, Amanitin-based HDP-103 was superior to an anti-PSMA Exatecan ADC. Adverse events with HDP-103 in non-human primates were restricted to known off-target effects of Amanitin-based ADCs, primarily in the liver and kidney. These effects can be readily monitored and are transient. HDP-103 serum levels demonstrate stability of the ADC in circulation, no evidence of drug accumulation, no differences between sexes, and dose-linearity. The potent anti-tumor efficacy of HDP-103 combined with a favorable half-life and a manageable safety profile, leads to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC. HDP-103´s unique mode of action gives it advantages over other treatment modalities in use or development for mCRPC including in patients with del(17p) who have a high unmet medical need.
공시 • Mar 12+ 1 more updateHeidelberg Pharma AG to Report Fiscal Year 2025 Results on Mar 26, 2026Heidelberg Pharma AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Mar 26, 2026
공시 • Nov 25+ 1 more updateHeidelberg Pharma AG Announces Board Changes, Effective 24 November 2025Heidelberg Pharma AG announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board, with immediate effect. Dr Liu has stepped down from his position as a member of the Supervisory Board of Heidelberg Pharma, with effect as of 23 December 2025. His permanent appointment as Chairman of the Executive Management Board will become effective as of 24 December 2025. For the transition period from 24 November 2025 until 23 December 2025 he will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz). Dr Liu is Chief Scientific Officer (CSO) and President of Huadong Global Development at Huadong Medicine in Hangzhou, China. Prior to that he held various leading positions in the pharma industry in the US, including GlaxoSmithKline, Wyeth (now Pfizer) and Forest Labs (now Abbvie). His more than 25 years of industry experience include clinical and preclinical research & development of medicinal products, including ADC products.
공시 • Sep 26+ 1 more updateHeidelberg Pharma AG Plans Significant Reduction in the Workforce by Approx. 75% by Mid-2026Heidelberg Pharma AG announced that Executive Management Board plans to reduce the workforce companywide by approximately 75% by mid-2026.
Breakeven Date Change • Aug 18No longer forecast to breakevenThe 2 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €94.9m in 2027. New consensus forecast suggests the company will make a loss of €33.6m in 2027.
공시 • Jul 11Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2025Heidelberg Pharma AG provided earnings guidance for the fiscal year 2025. For the period, the company expected sales revenue and other income to be in the range of EUR 9 million to EUR 11 million and operating loss to be in the range of EUR 30 million to EUR 35 million.
공시 • Apr 07Heidelberg Pharma AG, Annual General Meeting, May 15, 2025Heidelberg Pharma AG, Annual General Meeting, May 15, 2025, at 09:00 W. Europe Standard Time.
공시 • Mar 22Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2025Heidelberg Pharma AG provided earnings guidance for the fiscal year 2025. The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 9.0 million and EUR 11.0 million in sales revenue and other income (2024: EUR 12.0 million) in the 2025 fiscal year. Operating loss expected to be EUR 30.0 million to EUR 35.0 million.
공시 • Jan 24+ 1 more updateHeidelberg Pharma AG to Report Q2, 2025 Results on Jul 10, 2025Heidelberg Pharma AG announced that they will report Q2, 2025 results on Jul 10, 2025
공시 • Jan 13Heidelberg Pharma AG Progresses into Cohort 7 in A Phase I/IIa Study with Bcma Atac Candidate HDP-101 Targeting Multiple MyelomaHeidelberg Pharma AG announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose optimization regimens were introduced with three different settings. HDP-101 was well tolerated in Cohort 6, and the company are looking forward to publishing first efficacy and additional safety data of this patient group at forthcoming scientific conferences in 2025. Heidelberg Pharma's Phase I/IIa clinical study is an ongoing, non-randomised, open label study that is actively enrolling patients with relapsed or refractory Multiple myeloma or other plasma cell disorders expressing BCMA (B-cell maturation antigen). The study is currently assessing the safety, tolerability, pharmacokinetics, and efficacy of HDP-101 in patients with multiple myeloma. Clinical data from Cohort 5 demonstrated complete remission in one patient who had been heavily pre-treated across nine prior lines of therapy, including another BCMA-targeting agent. This patient showed an objective improvement (" partial response") in the 2nd cycle of treatment, with complete remission observed after the 11th cycle and continues sustaining response for more than a year.
Breakeven Date Change • Dec 30No longer forecast to breakevenThe 2 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €22.4m in 2026. New consensus forecast suggests the company will make a loss of €39.0m in 2026.
Reported Earnings • Oct 11Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023)Third quarter 2024 results: €0.13 loss per share (down from €0.002 profit in 3Q 2023). Revenue: €3.56m (up 59% from 3Q 2023). Net loss: €5.59m (down €5.71m from profit in 3Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 12Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)Second quarter 2024 results: €0.086 loss per share (improved from €0.20 loss in 2Q 2023). Revenue: €5.02m (up 117% from 2Q 2023). Net loss: €4.17m (loss narrowed 56% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
New Risk • May 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€34m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€34m free cash flow). Earnings have declined by 13% per year over the past 5 years.
Reported Earnings • Apr 26First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)First quarter 2024 results: €0.10 loss per share (improved from €0.14 loss in 1Q 2023). Revenue: €1.86m (down 10% from 1Q 2023). Net loss: €4.49m (loss narrowed 32% from 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.44 loss per share. Revenue: €16.8m (down 9.9% from FY 2022). Net loss: €20.3m (loss widened 3.3% from FY 2022). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is expected to decline by 6.3% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Germany are expected to grow by 17%.
Price Target Changed • Mar 08Price target increased by 14% to €8.85Up from €7.75, the current price target is provided by 1 analyst. New target price is 177% above last closing price of €3.19. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.53 last year.
공시 • Dec 12+ 2 more updatesHeidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024Heidelberg Pharma AG announced that they will report first half, 2024 results on Jul 11, 2024
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
Price Target Changed • Oct 25Price target decreased by 13% to €7.75Down from €8.87, the current price target is provided by 1 analyst. New target price is 176% above last closing price of €2.81. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.53 last year.
Reported Earnings • Oct 13Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)Third quarter 2023 results: EPS: €0.002 (up from €0.14 loss in 3Q 2022). Revenue: €9.50m (up 170% from 3Q 2022). Net income: €113.1k (up €4.73m from 3Q 2022). Profit margin: 1.2% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Germany are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
New Risk • Oct 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.2% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (€32m net loss next year).
공시 • Sep 19Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101Heidelberg Pharma AG announced that the clinical Phase I/IIa study with the lead development candidate HDP-101 has already started to recruit patients for the fifth patient cohort with a dosing of 100 µg/kg. The Safety Review Committee's (SRC) evaluation of patient data concluded that no dose-limiting toxicities have occurred to date. The first four dose levels have shown to be safe and well tolerated. So far 12 patients have been treated in the trial. With the expansion of study sites this summer, patient enrollment has significantly accelerated. One patient from the third cohort has now been on HDP-101 monotherapy for over nine months and has been treated with eleven doses. The BCMA antibody Amanitin conjugate HDP-101 is being tested in an open-label, multicenter study for the treatment of relapsed or refractory multiple myeloma, a cancer of the bone marrow. The first part of the study is a Phase I dose escalation study to determine the maximum tolerated dose of HDP-101. These findings will be used to determine the dose for the Phase IIa part, the primary objective of which is to initially evaluate the anti-tumor activity of HDP-101. The open-label, multicenter Phase I/IIa trial is expected to enroll up to 36 patients in the first part and up to 30 patients in the second part. Patients in Phase IIa will be stratified based on 17p deletion status. Preclinical data show that Amanitin has the potential to work particularly well on those tumors that have been genetically altered by a so-called 17p deletion to bypass a particular protective mechanism of cells. Patients with such a deletion generally respond less well to standard therapies and have a significantly poorer prognosis. Phase IIa will not only validate the efficacy of HDP-101 in patients with multiple myeloma, but also the clinical relevance of the 17p deletion.
Reported Earnings • Jul 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €2.50m (down 78% from 2Q 2022). Net loss: €9.39m (loss widened €8.03m from 2Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany.
공시 • May 09Heidelberg Pharma Ag Announces Executive ChangesHeidelberg Pharma AG announced that Walter Miller has been appointed Chief Financial Officer effective May 1, 2023. dr Jan Schmidt-Brand, who has held a dual role since 2014, will remain Spokesman of the Management Board/CEO and will hand over his responsibilities as CFO to Walter Miller. Walter Miller was most recently CFO of Optimapharm Group, a Clinical Research Organization (CRO) headquartered in Zagreb, Croatia, where he was responsible for finance, MA and administration. He has many years of experience in corporate finance, MA, strategic controlling, accounting and corporate development, both in biotech companies and at CROs. Before Optimapharm, Mr. Miller was CFO at Mologen AG, Berlin, and CFO at the Nuvisan Group, headquartered in Neu-Ulm, as well as more than ten years in senior finance positions at Santhera Pharmaceuticals, Pratteln, Switzerland. He holds a degree in business administration from Aachen University.
Price Target Changed • Apr 27Price target decreased by 19% to €8.87Down from €10.97, the current price target is an average from 3 analysts. New target price is 118% above last closing price of €4.06. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.70 next year compared to a net loss per share of €0.53 last year.
Price Target Changed • Apr 12Price target decreased by 19% to €8.87Down from €10.97, the current price target is an average from 3 analysts. New target price is 108% above last closing price of €4.27. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.70 next year compared to a net loss per share of €0.53 last year.
Breakeven Date Change • Mar 28No longer forecast to breakevenThe 3 analysts covering Heidelberg Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €24.0m in 2025. New consensus forecast suggests the company will make a loss of €27.0m in 2025.
Reported Earnings • Mar 27Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: €0.53 loss per share (improved from €0.80 loss in FY 2021). Revenue: €19.9m (up €17.8m from FY 2021). Net loss: €19.7m (loss narrowed 25% from FY 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Price Target Changed • Feb 07Price target decreased by 8.0% to €10.30Down from €11.20, the current price target is an average from 3 analysts. New target price is 106% above last closing price of €5.00. Stock is up 19% over the past year. The company is forecast to post a net loss per share of €0.64 next year compared to a net loss per share of €0.80 last year.
Reported Earnings • Oct 14Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)Third quarter 2022 results: €0.14 loss per share (improved from €0.17 loss in 3Q 2021). Revenue: €4.67m (up €4.11m from 3Q 2021). Net loss: €4.62m (loss narrowed 20% from 3Q 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Reported Earnings • Jul 13Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)Second quarter 2022 results: €0.04 loss per share (up from €0.22 loss in 2Q 2021). Revenue: €11.3m (up €10.7m from 2Q 2021). Net loss: €1.36m (loss narrowed 80% from 2Q 2021). Over the next year, revenue is forecast to grow 6.3%, compared to a 30% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Reported Earnings • May 01First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: €0.21 loss per share (down from €0.20 loss in 1Q 2021). Revenue: €829.0k (up 124% from 1Q 2021). Net loss: €7.25m (loss widened 15% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 295%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Price Target Changed • Mar 03Price target increased to €10.78Up from €9.95, the current price target is an average from 2 analysts. New target price is 101% above last closing price of €5.35. Stock is down 29% over the past year. The company is forecast to post a net loss per share of €0.72 next year compared to a net loss per share of €0.61 last year.
Reported Earnings • Oct 08Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: €633.8k (down 86% from 3Q 2020). Net loss: €5.76m (loss widened 89% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.
Executive Departure • Sep 03CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the companyDuring their tenure, earnings grew by 23% annually compared to the industry average of 20%. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Breakeven Date Change • Jul 12Forecast to breakeven in 2023The 4 analysts covering Heidelberg Pharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 12% per year to 2022. The company is expected to make a profit of €4.00m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Reported Earnings • Jul 09Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: €712.1k (down 56% from 2Q 2020). Net loss: €6.77m (loss widened 40% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.
Reported Earnings • May 01First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €461.5k (down 69% from 1Q 2020). Net loss: €6.32m (loss widened 38% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 27Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €9.58m (up 28% from FY 2019). Net loss: €18.4m (loss widened 81% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 17New 90-day high: €8.28The company is up 77% from its price of €4.69 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Price Target Changed • Feb 08Price target raised to €6.52Up from €5.62, the current price target is an average from 3 analysts. The new target price is 5.6% below the current share price of €6.90. As of last close, the stock is up 164% over the past year.
Is New 90 Day High Low • Dec 04New 90-day high: €5.32The company is up 30% from its price of €4.10 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.40 per share.
Is New 90 Day High Low • Nov 16New 90-day high: €4.88The company is up 9.0% from its price of €4.47 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.19 per share.
Is New 90 Day High Low • Oct 21New 90-day low: €3.55The company is down 22% from its price of €4.53 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €18.94 per share.
Reported Earnings • Oct 09Third quarter earnings releasedOver the last 12 months the company has reported total losses of €17.0m, with losses widening by 71% from the prior year. Total revenue was €8.80m over the last 12 months, up 27% from the prior year.
Is New 90 Day High Low • Sep 29New 90-day low: €3.83The company is down 19% from its price of €4.70 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.87 per share.